<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02916316</url>
  </required_header>
  <id_info>
    <org_study_id>FIL_Cardio-DLBCL</org_study_id>
    <nct_id>NCT02916316</nct_id>
  </id_info>
  <brief_title>Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell</brief_title>
  <official_title>Prospective Observational Study Investigating the Cardiotoxicity of Anthracyclines in Patients With Diffuse Large B-Cell</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Italiana Linfomi ONLUS</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Italiana Linfomi ONLUS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme
      R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline
      (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients
      (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of
      R-CHOP.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study was designed as a prospective observational multicenter study to evaluate the role
      of possible early markers of cardiotoxicity estimating an overall maximum risk equal to 20%
      of patients. The sample size, required to obtain an estimate of conventional anthracycline
      cardiotoxicity in the population, has been calculated with a confidence interval of 95% and a
      maximum acceptable error of ± 0.075. According to the conditions described above, the sample
      size of patients treated with conventional anthracycline results to be 124 patients.

      Considering a 10-15% of not evaluable patients, the sample size is fixed at 150 patients
      treated with R-CHOP. The duration of the enrollment phase is defined in 2 years.

      With this sample size should be possible to assess the risk of cardiotoxicity related to
      predictors with a worst group frequency at least of 10%.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiotoxicity</measure>
    <time_frame>1 year from enrollment</time_frame>
    <description>defined as the rate of cardiovascular events classified according to the Lenihan criteria 2013</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>6 months from enrollment</time_frame>
    <description>defined according to international criteria (Cheson 2007)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of response to treatment</measure>
    <time_frame>6 months from enrollment</time_frame>
    <description>defined according to international criteria (Cheson 2007)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years from enrollment</time_frame>
    <description>It will be calculated for all patients enrolled in the study from the date of start of therapy to the date of death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>3 years from enrollment</time_frame>
    <description>It will be calculated for all patients from the start of therapy given to the date of progression or death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>failure-free survival (FFS)</measure>
    <time_frame>3 years from enrollment</time_frame>
    <description>It will be calculated for all patients from the therapy start date to the date of an event or last follow-up.
The events considered for the FFS definition are the following: treatment discontinuation for toxicity, response &lt;RC, relapse / progression, death for any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From cardiovascular Event (FFCE)</measure>
    <time_frame>3 years from enrollment</time_frame>
    <description>calculated for all patients from the therapy start date to the time of occurrence of a cardiovascular event as defined by primary endopoint or follow-up date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of events recorded during the treatment and codified according to NCI-CTC v4.03</measure>
    <time_frame>3 years from enrollment</time_frame>
    <description>it will be defined by the number of events recorded during the treatment and codified according to NCI-CTC v4.03</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Lymphoma</condition>
  <condition>Large B-Cell</condition>
  <condition>Diffuse Large B-Cell</condition>
  <arm_group>
    <arm_group_label>Chemo immunotherapy</arm_group_label>
    <description>All patients enrolled in the study will have to be treated with a chemo immunotherapy scheme R-CHOP with doxorubicin, with doxorubicin analogue or non pegylated liposomal anthracycline (R-COMP; Sec. 648 DM) administered every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>R-CHOP with doxorubicin</intervention_name>
    <description>Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.</description>
    <arm_group_label>Chemo immunotherapy</arm_group_label>
    <other_name>R-CHOP with doxorubicin analogue</other_name>
    <other_name>R-COMP</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Diffuse Large B-Cell Lymphoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed Diffuse Large B-Cell Lymphoma diagnosis

          -  Patient eligible to receive 6 cycles of R-CHOP or R-CHOP like chemotherapy at full
             doses

          -  Age ≥ 18

          -  Stage I-IV

          -  Written informed consent

          -  ECOG Performance Status 0-3

          -  Ventricular Ejection Fraction (VEF) ≥40%

          -  No previous treatment for lymphoma (except for RT-IF)

          -  Negative β-HCG pregnancy test result at diagnosis for female of childbearing potential

          -  Use of acceptable method of contraception during the study and for 3 months after
             receiving the last dose of study drug for patients with childbearing potential

          -  Availability of the patient to be followed for all the phases of the chemotherapy
             treatment and for the subsequent follow-up

        Exclusion Criteria:

          -  Inability to schedule a treatment at full doses of chemoimmunotherapy R-CHOP or
             R-CHOP-like for different reasons

          -  Central nervous system involvement due to lymphoma

          -  HIV

          -  Active cardiac pathology including heart failure, left ventricular dysfunction
             documented by a LVEF &lt;40%, arrhythmias (rapid atrial fibrillation, frequent
             ventricular arrhythmias), valvular aortic or mitral disfunction &gt; moderate, ischemic
             heart disease (myocardial infarction or acute coronary syndrome for over 6 months,
             angina at rest or with mild efforts)

          -  Previous treatment for lymphoma

          -  Other malignancy in the 3 years prior to the diagnosis of lymphoma with exception of
             non-melanoma skin cancer or in situ carcinoma

          -  Any other co-existing medical condition that would preclude participation in the study
             (uncontrolled bacterial or viral or fungal infection)

          -  Pregnant, or lactating and breastfeeding female
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Luminari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNIVERSITÀ DEGLI STUDI DI MODENA E REGGIO EMILIA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefania Badiali</last_name>
    <phone>0039 059 422 4501</phone>
    <email>sbadiali@filinf.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dondi Alessandra</last_name>
    <phone>0039 059 422 2019</phone>
    <email>adondi@filinf.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>U.O.C. Garibaldi Nesima</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ugo Consoli, MD</last_name>
      <phone>+39 095-7595057</phone>
      <email>ugo.consoli@tin.it; ematologia.nesima@alice.it</email>
    </contact>
    <investigator>
      <last_name>Ugo Consoli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Divisione di Ematologia, Centro Trapianto di Cellule Staminali</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>Foggia</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicola Cascavilla</last_name>
      <phone>0039 0882 410999</phone>
      <email>n.cascavilla@operapadrepio.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Cascavilla</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AO Riuniti Papardo Piemonte</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donato Mannina, MD</last_name>
      <phone>090-3992239</phone>
      <email>donamanni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Donato Mannina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Oncologia Medica ed Ematologia Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armando Santoro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Armando Santoro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale Niguarda Ca' Granda</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chiara Rusconi, MD</last_name>
      <phone>0039 02 64447597</phone>
      <email>chiara.rusconi@ospedaleniguarda.it</email>
    </contact>
    <investigator>
      <last_name>Chiara Rusconi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nuovo Ospedale Di Sassuolo S.P.A.</name>
      <address>
        <city>Sassuolo</city>
        <state>Modena</state>
        <zip>41049</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Giovanni Partesotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Policlinico Di Modena</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stefano Sacchi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Villa Sofia - Cervello</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Patti, MD</last_name>
      <phone>+39 091-6884002</phone>
      <email>k.patti@ospedaliriunitipalermo.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Patti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia Azienda Ospedaliero Universitaria Paolo Giaccone</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatrice Mancuso</last_name>
      <email>svmancuso@libero.it</email>
    </contact>
    <investigator>
      <last_name>Salvatrice Mancuso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia e CTMO di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Annalisa Arcari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro di riferimento Oncologico Oncologia Medica A</name>
      <address>
        <city>Aviano</city>
        <state>Pordenone</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Spina, MD</last_name>
      <phone>+39 0434/659730</phone>
      <email>mspina@cro.it</email>
    </contact>
    <investigator>
      <last_name>Michele Spina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Bianchi - Melacrino - Morelli</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Stelitano, MD</last_name>
      <phone>0039 0965397653</phone>
      <email>cstelit@libero.it</email>
    </contact>
    <investigator>
      <last_name>Caterina Stelitano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale S. Giacomo di Castelfranco Veneto</name>
      <address>
        <city>Castelfranco Veneto</city>
        <state>Treviso</state>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Sartori, MD</last_name>
      <phone>0423-732346</phone>
      <email>roberto.sartori@ulssasolo.ven.it</email>
    </contact>
    <investigator>
      <last_name>Nilla Maschio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti - Ospedale Umberto I Di Ancona</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>g.gini@ospedaliriuniti.marche.it</email>
    </contact>
    <investigator>
      <last_name>Guido Gini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UO Ematologia PO Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Di Renzo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dario Marino, MD</last_name>
      <phone>049-8215621</phone>
      <email>marino.dario@libero.it</email>
    </contact>
    <investigator>
      <last_name>Dario Marino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Complessa di Ematologia Ospedale di Parma</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesca Re</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Di S. Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Merli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ematologia e Trapianto Istituto Regina Elena IFO</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Palombi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Francesca Palombi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osp.Sant'Eugenio Divisione di Ematologia</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabetta Abruzzese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994 Sep 1;84(5):1361-92. Review.</citation>
    <PMID>8068936</PMID>
  </reference>
  <reference>
    <citation>Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993 Apr 8;328(14):1002-6.</citation>
    <PMID>7680764</PMID>
  </reference>
  <reference>
    <citation>International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993 Sep 30;329(14):987-94.</citation>
    <PMID>8141877</PMID>
  </reference>
  <reference>
    <citation>Tilly H, Lepage E, Coiffier B, Blanc M, Herbrecht R, Bosly A, Attal M, Fillet G, Guettier C, Molina TJ, Gisselbrecht C, Reyes F; Groupe d'Etude des Lymphomes de l'Adulte. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood. 2003 Dec 15;102(13):4284-9. Epub 2003 Aug 14.</citation>
    <PMID>12920037</PMID>
  </reference>
  <reference>
    <citation>Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rudolph C, Reiser M, Hossfeld DK, Metzner B, Hasenclever D, Schmitz N, Glass B, Rübe C, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):626-33. Epub 2004 Feb 24.</citation>
    <PMID>14982884</PMID>
  </reference>
  <reference>
    <citation>Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller AC, Rübe C, Rudolph C, Reiser M, Hossfeld DK, Eimermacher H, Hasenclever D, Schmitz N, Loeffler M; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004 Aug 1;104(3):634-41. Epub 2004 Mar 11.</citation>
    <PMID>15016643</PMID>
  </reference>
  <reference>
    <citation>Balzarotti M, Spina M, Sarina B, Magagnoli M, Castagna L, Milan I, Ripa C, Latteri F, Bernardi D, Bertuzzi A, Nozza A, Roncalli M, Morenghi E, Tirelli U, Santoro A. Intensified CHOP regimen in aggressive lymphomas: maximal dose intensity and dose density of doxorubicin and cyclophosphamide. Ann Oncol. 2002 Sep;13(9):1341-6.</citation>
    <PMID>12196358</PMID>
  </reference>
  <reference>
    <citation>Vitolo U, Liberati AM, Cabras MG, Federico M, Angelucci E, Baldini L, Boccomini C, Brugiatelli M, Calvi R, Ciccone G, Genua A, Deliliers GL, Levis A, Parvis G, Pavone E, Salvi F, Sborgia M, Gallo E; Intergruppo Italiano Linfomi. High dose sequential chemotherapy with autologous transplantation versus dose-dense chemotherapy MegaCEOP as first line treatment in poor-prognosis diffuse large cell lymphoma: an &quot;Intergruppo Italiano Linfomi&quot; randomized trial. Haematologica. 2005 Jun;90(6):793-801.</citation>
    <PMID>15951292</PMID>
  </reference>
  <reference>
    <citation>Wilson WH. Chemotherapy sensitization by rituximab: experimental and clinical evidence. Semin Oncol. 2000 Dec;27(6 Suppl 12):30-6. Review.</citation>
    <PMID>11225998</PMID>
  </reference>
  <reference>
    <citation>Demidem A, Lam T, Alas S, Hariharan K, Hanna N, Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm. 1997 Jun;12(3):177-86.</citation>
    <PMID>10851464</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2016</study_first_submitted>
  <study_first_submitted_qc>September 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2016</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Large B-Cell</keyword>
  <keyword>Cardiotoxicity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiotoxicity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

